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Abstract 
Portions of the extracellular domain of the platelet-derived growth factor receptor p (PDGFR-/I) were expressed as fusion proteins with a hexa 
His tag in E. co/i. Following purification by Ni chelate chromatography, the recombinant receptors were tested in cross-competition studies with 
“51-labelled PDGF-AA and -BB. Although of lower affinity than the native receptor (IC,, values of IO-@ M) the recombinant molecules retained 
ligand binding specificity and neutral&d the mitogenic effect of PDGF-BB. These data indicate that the ligand binding region lies within the first 
four immunoglobulin-like domains on PDGFR-/?. This E. coli expression system could be further used as a rapid and economical means to produce 
mutated receptors and map the ligand binding domain. 
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1. Introduction 
Platelet derived growth factor (PDGF) is an important 
chemoattractant and mitogen for cells of mesenchymal 
origin and is thought to play an important role in embry- 
ogenesis and wound repair. PDGF has also been impli- 
cated in a number of pathological processes uch as arte- 
riosclerosis, tumourogenesis, glomerulonephritis, and 
rheumatoid arthritis (reviewed in [l]). PDGF is a di- 
sulphide-linked imer of two related polypeptide chains, 
designated A and B, which are assembled as hetero- 
dimers (PDGF-AB) or homodimers (PDGF-AA or 
PDGF-BB) [2]. All three possible isoforms have been 
isolated and shown to bind with different affinities to two 
different but related receptor molecules, designated 
PDGFR-ol and PDGFR-B [3,4]. The PDGFR-a binds all 
three isoforms of PDGF, while PDGFR-/3 exhibits high- 
affinity binding only for PDGF-BB [5]. Ligand-induced 
dimerisation of the PDGFRs has been shown to activate 
*Correspondmg author. Present address.. Research School of Bio- 
sciences, University of Kent at Canterbury, Kent, CT2 7NJ, UK. Fax: 
(44) 227 763912. 
the receptor’s intrinsic intracellular tyrosine kinase do- 
mains [6] which subsequently leads to phosphorylation 
of target intracellular signalling molecules and mediation 
of a cellular response [l]. 
Major advances have been made in our understanding 
of the structure of the PDGF ligand by solving the crys- 
tal structure [7], and the sites of interaction with the 
receptor by site-directed mutagenesis [8-lo], but it is still 
unclear how the receptor interacts with its anti-parallel 
dimeric ligand. 
The extracellular domains of both receptors exhibit a 
similar pattern of cysteine spacing which putatively sub- 
divides them into five immunoglobulin-like domains 
(Dl-D5) Fig. 1 [l 11. Work carried out on PDGFR-ol 
implicated the N-terminal IgG-like domains (Dl-D3) as 
specifying binding of PDGF-AA [ 12,131 but little is 
known about binding to the /3 receptor. Although both 
the CI andp receptors have similar domain arrangements, 
a specific antagonist (neomycin) for PDGF-BB binding 
to 01 did not affect binding to p [14]. 
In order to understand the nature of PDGF binding 
to the p receptor, various fragments of the extracellular 
domain of PDGFR-/? were expressed in E. coli . Follow- 
ing purification the binding ability of these recombinant 
receptors was examined in cross-competition experi- 
ments with cell-bound receptors. Results obtained indi- 
cate areas of importance for ligand binding on the 
PDGFR-/? molecule. 
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2. Materials and methods 
2.1. Construction of recombinant E. coli expression vectors 
Fragments of the PDGFR-p cDNA (kindly provided by M. Murray, 
Zymogenetics, Seattle, USA [1_5]) were cloned into BarnHI site on the 
expression plasmid pDS781RBSll [I61 which contains an inducible pro- 
moter, and generates fusion proteins with six histidine residues at the 
amino terminal. The PDGFR-/I fragments 1 and 11 were generated by 
digesting the cDNA with SmaI (which removes codons for the signal 
sequence at the 5’ end) and SphI and FspI at the 3’ end respectively (Fig. 
1). Construct $111 was also produced by SmaI digestion at the 5’ end 
but a new Hind111 site was introduced by site directed mutagenesis at 
nucleotide position 1957 (Zymogenetics, Seattle, US) and resulted in a 
fragment of DNA coding for the full extracellular domain of the recep- 
tor. 
2.2. Expression of recombrnant PDGFR-p 
E. coli Ml5 cells containing the plasmid pDMI,l (lac repressor) were 
transformed with the receptor constructs $1, @II and rfiII1. The cells 
were grown to an OD, of 0.7, when protein production was Induced 
by IPTG addition (2 mM) and incubated for a further 4 h before 
harvesting as described by Hochuli et al. [16]. The recovered biomass 
was lysed overnight at room temperature in 6 M guanidine hydroclo- 
ride in 0.1 M sodium phosphate buffer pH 8. Following centrifugation 
(4,000 x g, 10 min, 4°C) the resultant supernatant was applied to a 
nickel chelate column. The chromatography was performed in 8 M 
Urea , 0.1 M sodium phosphate buffer and was developed with a pH 
step gradient (load crude extract - pH 8, wash steps - pH 8 and pH 6, 
product elution - pH 4). Collected fractions were dialysed against PBS, 
analysed by SDS-PAGE and tested for activity. 
3.3. BIological activity of recombrnant receptors (r/Q 
The ability of recombinant PDGF receptors @I, $11 and $111 to 
bind PDGF-AA and -BB was measured by cross-competition with 
native receptors on Swiss 3T3 cells for [‘251]PDGF binding using stand- 
ard protocols [17]. In brief, the cells were Incubated simultaneously with 
E. coli derived receptors and [‘*?]PDGF-AA or -BB, and specific bind- 
mg was determined after 3 h at 4°C. Non-specific binding was deter- 
mined using 50 &ml of the unlabelled PDGF isoform. 
The inhibition of the mitogenic effects of PDGF-BB and PDGF-AA 
ligands, and epidermal growth factor (EGF) by recombinant receptors 
was carried out as described previously [18]. Swiss 3T3 cells were incu- 
bated with PDGF-AA, -BB or EGF for 20 h at 37°C when DNA 
synthesis was measured by [rH]thymidine incorporation over 2 h. In 
parallel $1 or r/III was incubated with the cells and mitogens, and 
neutralisation of the of mitogenic effect examined. 
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Domain arrangement of PDGF-receptor /I and recombinant 
constructs $I-III. ss = signal sequence, Dl-D5 = extracellular IgG-like 
domains [ 1, TMD = trans-membrane domain, TKl + TK2 = split ty- 
rosine kinase domains, o and C = conserved cysteme restdues, I = po- 
tential sites for N-linked glycosylation, 6x H = hexa histidine tag, sites 
of restriction digest indicated by arrows 
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Fig. 2. Cross-competition binding of [‘251]PDGF to Swiss 3T3 cells. 
Binding of [“‘I]PDGF-BB was competed by increasing amounts of $1 
(m), $11 (o), $111 (*) or [“‘I]PDGF-AA by increasing amounts of $1 
@I), $11 (0) and bound radioactivity was measured in triplicate as 
described in Section 2. Non-specific binding of [‘?]PDGF-AA or -BB 
was determined by the addition of 50 &ml unlablled PDGF-AA or 
-BB, respectively. Relative specific binding IS plotted as percent of 
specific binding of labelled PDGF-BB in the absence of unlabelled 
PDGF. 
3. Results and discussion 
Although much progress has been made in our under- 
standing of the sites of interaction between the activated 
tyrosine kinase domain of the PDGF receptor and its 
downstream target signalling molecules [1,19] less is 
known about the binding of the PDGF ligand to the 
extracellular domain of the receptor and the mechanism 
of dimerisation. Work with chimeric receptors indicate 
that the first three IgG-like domains (Dl-3) of PDGFR- 
a contain PDGF-AA binding determinants and deletion 
of IgG-like domain 2 implicates this domain in high- 
affinity binding [12,13]. Indeed recent experiments car- 
ried out on recombinant PDGFR-a and PDGFR-/3 (ex- 
pressed in insect cells) has suggested the presence of two 
binding sites for PDGF on the receptors [5]. In combina- 
tion with recent information on the structure of the 
PDGF ligand [7] a new model for receptor-ligand inter- 
action was suggested [5]. Rather than one receptor sub- 
unit intracting with only one chain of the PDGF dimer 
[20], the subunit may interact with domains on both 
chains of the anti-parallel igand dimer but more detailed 
structural information is required to determine this. In 
this study fragments of the extracellular domain of 
PDGFR-B were expressed in E. coli in an attempt to 
understand more fully its binding to its ligand. 
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Using convenient restriction sites in the PDGFR-/? 
cDNA (Fig. 1) two truncated (r/31, $11) and one full- 
length (@III) extracellular portions of the receptor were 
expressed as fusion proteins to six histidines in E. coli. 
and purified. The apparent molecular masses of 43 kDa 
for $1, 50 kDa for $11, and 53 kDa for $111 (Fig. 4A) 
were as predicted from published cDNA sequence [151. 
By carrying out cross-competition experiments with na- 
tive cell bound receptors on Swiss 3T3 cells the ability to 
bind PDGF-BB ligand specifically and not PDGF-AA 
was demonstrated (Fig. 2). IC 50 values of 1, 3 and 4 
x 10m8 M for PDGF-BB were calculated for $1. $11, 
and $111, respectively. 
The ability to inhibit specifically the mitogenic effect 
of PDGF-BB and not the effect of PDGF-AA or the 
unrelated mitogen epidermal growth factor (EGF) on 
Swiss 3T3 cells can be seen in Fig. 3 ($111 not shown). 
These results indicate that fragments of PDGFR-/I ex- 
pressed in E. coli still retain the same ligand binding 
specificity as native PDGFR-fi and only recognise 
PDGF-BB [ 151. 
The lower affinity of these recombinant receptors 
when compared to a construct similar to $111 expressed 
in insect cells (4.8 x lo-‘M) [5] may be due to differences 
in post-translational processing between prokaryotic 
and eukaryotic expression systems. There are eleven po- 
tential glycosylation sites on the extracellular domain of 
PDGFR-b (nine on @I) and as oligosaccharides are 
known to play an important role in many molecular 
recognition events [21] their absence from the recombi- 
nant E. coli molecules may lower the affinity. Also at 
high local concentrations PDGFR extracellular domains 
have been shown to oligomerise even in the absence of 
ligand [5]. When $1, r/311 and r$?III are examined under 
non reducing conditions (Fig. 4B) aggregates were ap- 
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Fig. 3. Effect of recombinant receptors on stimulation of DNA synthe- 
sis in Swiss 3T3 cells by PDGF-AA,-BB, or EGF. [‘HJThymidine incor- 
poration was measured following exposure of cells to 1 &ml of each 
growth factor as described in section 2. Increasing amounts of recom- 
binant receptors were added and percent reduction/increase in stimula- 
tion was calculated. 
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Fig. 4 SDS/PAGE of recombinant receptors. Recombinant proteins 
$1 = lane 1, $11 = lane2, @III = lane 3 were electrophoresed in 10% 
polyacrylamide gel in the presence A, or absence B of reducing agent. 
Molecular weight standards are as indicated. 
parent which may be due to oligomerisation and/or im- 
proper disulphide bond formation. These aggregates 
may affect the affinity of the receptor for its ligand, or 
produce a mixed population of improperly folded inac- 
tive aggregates and properly folded high affinty mole- 
cules at low concentration, which could also be responsi- 
ble for the lower affinity of the fragments expressed in 
E. coli. 
It is interesting to note that the truncated extracellular 
forms of the receptor $1 and $11, display a similar 
binding affinity as the complete extracellular form $111. 
In the case of $1 the immunoglobulin like domain D5 
is absent as depicted in Fig. 1. This would imply that this 
domain is not essential for ligand binding and that do- 
mains l-4 play a major role in ligand-receptor interac- 
tion and specificity. This has also been indicated in stud- 
ies using chimeras of the a and /I receptors which maps 
specificity for PDGF-AA to these domains on the a re- 
ceptor [12]. Interestingly a truncated form of the murine 
/I receptor which lacks domains l-3 has been reported 
and is postulated to act in a developmentally regulated 
manner even in the absence of ligand 1221. 
This work demonstrates that it is possible to produce 
soluble forms of the PDGFR-/I in E. coli which display 
characteristics of the native cell-bound receptor and 
which preserve the ligand binding specificity for PDGF- 
BB as predicted for the full-length receptor [15]. The 
lower affinity may be due to improper post-translational 
processing of the recombinant receptors in E. co/i but 
these molecules may also lack domains which are re- 
quired for stable high affinity binding and dimerisation. 
However this work suggests that this expression system 
could be further used as a rapid means to produce mu- 
tated and defined regions of the extracellular domain of 
the PDGF receptors and map the sites of ligand interaction. 
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